7-methylxanthine has been researched along with Disease Exacerbation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, D; Guggenheim, J; Ribel-Madsen, S; Trier, K | 1 |
| Ohno-Matsui, K; Vutipongsatorn, K; Yokoi, T | 1 |
1 review(s) available for 7-methylxanthine and Disease Exacerbation
| Article | Year |
|---|---|
Current and emerging pharmaceutical interventions for myopia.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Atropine; Clinical Trials as Topic; Disease Progression; Drug Evaluation, Preclinical; Drug Therapy; Humans; Ketorolac Tromethamine; Mydriatics; Myopia; Pharmaceutical Preparations; Riboflavin; Vitamin B Complex; Xanthines | 2019 |
1 other study(ies) available for 7-methylxanthine and Disease Exacerbation
| Article | Year |
|---|---|
Oral administration of caffeine metabolite 7-methylxanthine is associated with slowed myopia progression in Danish children.
Topics: Administration, Oral; Adolescent; Axial Length, Eye; Caffeine; Child; Denmark; Disease Progression; Humans; Myopia; Refraction, Ocular | 2023 |